A Phase II Trial of Cisplatin (C), Gemcitabine (G) and Gefitinib for Advanced Urothelial Tract Carcinoma: Results of Cancer and Leukemia Group B (CALGB) 90102

Overview

Journal Ann Oncol

Publisher Elsevier

Specialty Oncology

Date 2009 Jan 27

PMID 19168670

Citations 40

Authors

G K Philips

S Halabi

B L Sanford

D Bajorin

E J Small

Affiliations

Soon will be listed here.

Abstract

Background: This phase II trial (Cancer and Leukemia Group B 90102) sought to determine the efficacy of cisplatin, standard infusion of gemcitabine and gefitinib in patients with advanced urothelial carcinoma.

Patients And Methods: Eligible patients had previously untreated measurable disease, Eastern Cooperative Oncology Group (ECOG) performance status of zero to two and creatinine clearance >50 ml/min. Treatment consisted of cisplatin 70 mg/m(2) day 1 and gemcitabine 1000 mg/m(2) on days 1 and 8 given every 3 weeks concurrent with gefitinib 500 mg/day orally for six cycles. Maintenance gefitinib 500 mg/day was continued for responding or stable disease.

Results: Fifty-four of 58 patients were assessable. Twelve patients (22%) had node-only disease, and 25 (46%) had an ECOG performance status of zero. There were 23 objective responses for an overall response rate of 42.6% [95% confidence interval (CI) 29.2% to 56.8%]. The median survival time was 15.1 months (95% CI 11.1-21.7 months) and the median time to progression was 7.4 months (95% CI 5.6-9.2 months).

Conclusions: The combination of cisplatin, gemcitabine and gefitinib is well tolerated and active in advanced transitional cell carcinoma. The addition of gefitinib does not appear to improve response rate or survival in comparison to historical controls of cisplatin and gemcitabine alone.

Citing Articles

Macrophage-organoid co-culture model for identifying treatment strategies against macrophage-related gemcitabine resistance.

Jiang S, Deng T, Cheng H, Liu W, Shi D, Yuan J J Exp Clin Cancer Res. 2023; 42(1):199.

PMID: 37553567 PMC: 10411021. DOI: 10.1186/s13046-023-02756-4.

The role of switch maintenance therapy in urothelial cancers.

Yu E, Mudireddy M, Biswas R, Aragon-Ching J Ther Adv Urol. 2023; 15:17562872221147760.

PMID: 36891217 PMC: 9986508. DOI: 10.1177/17562872221147760.

Developing Precision Medicine for Bladder Cancer.

Guercio B, Iyer G, Rosenberg J Hematol Oncol Clin North Am. 2021; 35(3):633-653.

PMID: 33958155 PMC: 8108703. DOI: 10.1016/j.hoc.2021.02.008.

Novel Tyrosine Kinase Targets in Urothelial Carcinoma.

Torres-Jimenez J, Albarran-Fernandez V, Pozas J, Roman-Gil M, Esteban-Villarrubia J, Carrato A Int J Mol Sci. 2021; 22(2).

PMID: 33451055 PMC: 7828553. DOI: 10.3390/ijms22020747.

Systemic treatment for advanced urothelial cancer: an update on recent clinical trials and current treatment options.

Park I, Lee J Korean J Intern Med. 2020; 35(4):834-853.

PMID: 32668516 PMC: 7373963. DOI: 10.3904/kjim.2020.204.

References

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

Tempero M, Plunkett W, Ruiz Van Haperen V, Hainsworth J, Hochster H, Lenzi R . Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol. 2003; 21(18):3402-8. DOI: 10.1200/JCO.2003.09.140. View

Turkeri L, Erton M, Cevik I, Akdas A . Impact of the expression of epidermal growth factor, transforming growth factor alpha, and epidermal growth factor receptor on the prognosis of superficial bladder cancer. Urology. 1998; 51(4):645-9. DOI: 10.1016/s0090-4295(97)00648-1. View

Gandhi V, Plunkett W, Du M, Ayres M, Estey E . Prolonged infusion of gemcitabine: clinical and pharmacodynamic studies during a phase I trial in relapsed acute myelogenous leukemia. J Clin Oncol. 2002; 20(3):665-73. DOI: 10.1200/JCO.2002.20.3.665. View

Blehm K, Spiess P, Bondaruk J, Dujka M, Villares G, Zhao Y . Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res. 2006; 12(15):4671-7. DOI: 10.1158/1078-0432.CCR-06-0407. View

Ciardiello F, Caputo R, Bianco R, Damiano V, Pomatico G, De Placido S . Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res. 2000; 6(5):2053-63. View

Kassouf W, Dinney C, Brown G, McConkey D, Diehl A, Bar-Eli M . Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res. 2005; 65(22):10524-35. DOI: 10.1158/0008-5472.CAN-05-1536. View

Herbst R, Prager D, Hermann R, Fehrenbacher L, Johnson B, Sandler A . TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol. 2005; 23(25):5892-9. DOI: 10.1200/JCO.2005.02.840. View

Cappellen D, de Oliveira C, Ricol D, de Medina S, BOURDIN J, Sastre-Garau X . Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999; 23(1):18-20. DOI: 10.1038/12615. View

10.

Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve B, Hicklin D . Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 1999; 5(2):257-65. View

11.

von der Maase H, Sengelov L, Roberts J, Ricci S, Dogliotti L, Oliver T . Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005; 23(21):4602-8. DOI: 10.1200/JCO.2005.07.757. View

12.

Bajorin D, Dodd P, Mazumdar M, Fazzari M, McCaffrey J, Scher H . Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999; 17(10):3173-81. DOI: 10.1200/JCO.1999.17.10.3173. View

13.

Lipponen P, Eskelinen M . Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer. 1994; 69(6):1120-5. PMC: 1969432. DOI: 10.1038/bjc.1994.220. View

14.

Giaccone G, Herbst R, Manegold C, Scagliotti G, Rosell R, Miller V . Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. J Clin Oncol. 2004; 22(5):777-84. DOI: 10.1200/JCO.2004.08.001. View

15.

Sirotnak F, Zakowski M, Miller V, Scher H, Kris M . Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res. 2001; 6(12):4885-92. View

16.

Als A, Sengelov L, von der Maase H . Gemcitabine and cisplatin in locally advanced and metastatic bladder cancer; 3- or 4-week schedule?. Acta Oncol. 2007; 47(1):110-9. DOI: 10.1080/02841860701499382. View

17.

Parra H, Cavina R, Latteri F, Sala A, DAmbrosio M, Antonelli G . Three-week versus four-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. Ann Oncol. 2002; 13(7):1080-6. DOI: 10.1093/annonc/mdf186. View

18.

Dominguez-Escrig J, Kelly J, Neal D, King S, Davies B . Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer. Clin Cancer Res. 2004; 10(14):4874-84. DOI: 10.1158/1078-0432.CCR-04-0034. View

19.

Bue P, Wester K, Sjostrom A, Holmberg A, Nilsson S, Carlsson J . Expression of epidermal growth factor receptor in urinary bladder cancer metastases. Int J Cancer. 1998; 76(2):189-93. DOI: 10.1002/(sici)1097-0215(19980413)76:2<189::aid-ijc4>3.0.co;2-t. View

20.

Bellmunt J, Hussain M, Dinney C . Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family. Crit Rev Oncol Hematol. 2003; 46 Suppl:S85-104. DOI: 10.1016/s1040-8428(03)00067-2. View